Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and begins dosing first patient with second cycle of therapy

Celyad advances THINK trial to third and final dose level in hematological study arm Second cycle treatment amendment in THINK protocol approved and first patient dosed Regulatory News: Celyad (Pa...

More From BioPortfolio on "Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and begins dosing first patient with second cycle of therapy"